Eagle Pharmaceuticals, Inc.
EGRX · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.08 | -0.53 | -0.03 | 0.39 |
| FCF Yield | -0.05% | -9.06% | 9.87% | -3.81% |
| EV / EBITDA | 19.03 | 24.55 | 18.29 | 183.03 |
| Quality | ||||
| ROIC | 1.75% | 1.07% | 1.92% | -59.08% |
| Gross Margin | 73.92% | 73.91% | 67.27% | 64.11% |
| Cash Conversion Ratio | -0.02 | -5.83 | 4.60 | 3.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.82% | 13.42% | 19.02% | 17.01% |
| Free Cash Flow Growth | 99.61% | -189.41% | 383.65% | -130.79% |
| Safety | ||||
| Net Debt / EBITDA | 3.45 | 3.15 | 0.34 | 21.38 |
| Interest Coverage | 7.12 | 4.08 | 4.78 | -1.45 |
| Efficiency | ||||
| Inventory Turnover | 0.40 | 0.39 | 0.42 | 0.37 |
| Cash Conversion Cycle | 304.11 | 298.11 | 239.37 | 326.44 |